Ophthalmology entrepreneur based in Barcelona that led the foundation of AVX Pharma in 2013 and has been key in securing both financing and a strong team to bring AVX Pharma lead candidate AVX-012 into clinical development and drive the company at the forefront of innovation in Dry Eye Syndrome.
Roger is one of the founders of Inveready Group and took part of the original team that positioned the Group to advise start-ups.
Roger joined Inveready Capital, the investment division of the Group, from inception. To date, Roger has participated in 21 investments made by the vehicle and is an advisor in Password Bank, 3Scale and Adman Media.
Currently Investment Director of Inveready’s Biotechnology Fund, where she screens, invests and manages investments in Drug Development, Molecular Diagnostics, Nutraceuticals and Medical Devices.
Since February 2013 Sara has been Investment Director at
Inveready Asset Management, a Barcelona based Seed
Venture Capital group focusing on IT and biotechnology.
From 2006 to 2013 Sara was first consultant and then
Director of Spin-outs for the University of Barcelona, where
she helped launch and finance over 25 start-ups and
negotiated numerous technology licences. Her prior
experience includes working as an analyst for Chevron
Technology Ventures, the Corporate Venture Capital Fund
of the US’s second largest integrated oil company, with US
210 Million under management, where she was involved in
investing and successfully exiting energy-related
Sara also worked for Dames and Moore (now URS Corp),
the environmental consultancy firm, in the US, Canada and
Latin America as well as the World Bank and the
International Finance Corporation. She holds a BS in
Chemistry from the University of Barcelona, a Master’s in
Environmental Science from Indiana University, and an
MBA from the London Business School.
She collaborates with the European Commission as an expert in innovation.